Showing 1-10 of 13

Sorted By:

  • Breast Cancer: CALGB 49907 (Hematology Oncology Associates)

    To compare the effectiveness of standard chemotherapy regimens (Cyclophosphamide, Methotrexate and Fluorouracil [CMF] or Doxorubicin and Cyclophosphamide [AC]) with single agent Capecitabine with respect to disease-free survival in women 65 years and older with local and regional breast cancer.

  • Breast Cancer: CTSU E5103 (Hematology Oncology Associates)

    The purpose of this study is to determine if adding a medication by the name of bevacizumab to the current standard chemotherapy of cancer-reducing medications, namely doxorubicin, cyclophosphamide and paclitaxel, reduces the risk of recurrence (called disease-free survival) compared to standard chemotherapy alone.

  • Breast Cancer: E2112 (Hematology Oncology Associates)

    The purpose of this study is find out what effects, both good and bad, an experimental drug called entinostat has on patients with breast cancer that is not able to be removed by surgery or has spread to another part of the body, when given together with the standard hormonal drug treatment, exemestane.

  • Breast Cancer: N063D (Hematology Oncology Associates)

    This purpose of this research study is to find out what effects (good and bad) the study treatment has on patients with early stage HER2 positive (HER2+) breast cancer that has been surgically removed.

  • Breast Cancer: PACCT-1 (Hematology Oncology Associates)

    The purpose of this study is to determine whether patients who have a tumor with an Oncotype DX Recurrence Score of 11-25 benefit from chemotherapy, and to confirm that patients who have Oncotype DX Recurrence Score of < 10 have a very low risk of recurrence with hormonal therapy alone (and do not need chemotherapy to reduce their risk of recurrence).

  • Breast Cancer: SWOG S0221 (Hematology Oncology Associates)

    The main purpose of this study is to compare the effects (good and bad) of two different treatments (or “regimens”) for breast cancer that is considered high risk. These two treatments include essentially the same drugs given in different ways and on different schedules. All of the treatments use standard, commercially available medicines that are known to be effective for treating breast cancer.

  • Colon Cancer: CTSU E5202 (Hematology Oncology Associates)

    This study will also compare the effects (good and bad) of a combination of chemotherapy drugs, when given with and without a new drug, bevacizumab, on patients with stage II colon cancer at high-risk for recurrence.

  • Kidney Cancer: CTSU E2805 (Hematology Oncology Associates)

    Kidney Cancer: CTSU E2805 (Iowa Cancer Specialists)

  • Lung (Non-Small Cell) Cancer: CTSU E1505 (Hematology Oncology Associates)

    The purpose of this study is to determine if adding the new drug bevacizumab to chemotherapy improves the chance for cure for patients who have had surgery for the removal of the lung cancer.

  • Lung (Non-Small Cell) Cancer: E2511 (Hematology Oncology Associates)

    The purpose of this study to compare the effects, good and/or bad, of veliparib or a dummy pill (placebo) when combined with the standard commonly-used drugs (cisplatin and etoposide) on patients with small cell cancer of the lung or large cell neuroendocrine non-small cell cancer of the lung to find out which is better.

Page InfoPage
Page of 2, showing trials 1-10 of 13

View Additional Section Content

Contact Us

For more information about our research program and IRB, please contact:

Research Support Office
563-421-7955

Email